SEC Form 4 · accession 0001209191-15-022712
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erle T Mast
Officer — Executive VP and CFO
Period of report
Mar 2, 2015
Accepted (ET)
Mar 4, 2015 · 9:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $79.05 | Mar 2, 2015 | A | 35,000 | A | — | Mar 2, 2025 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The option shall vest as to 12.5% of the shares on March 2, 2016, and as to 37.5% of the shares in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 25% of the shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib and the remaining 25% shall vest upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib.